Private-label omeprazole gets final OK
This article was originally published in The Tan Sheet
Executive Summary
FDA grants final approval to Israel-based Dexcel Pharma Technologies' 20 mg omeprazole delayed-release tablets, Perrigo announces Dec. 10. Perrigo will be the exclusive marketer and distributor of the store brand Prilosec OTC, and plans to begin distribution of the product during the first quarter of 2008, the Allegan, Mich.-private labeler states. The firm expects the generic omeprazole product to contribute $150 mil. to $200 mil. in sales in 2008, according to a release. The upcoming launch of the omeprazole product, which Perrigo CEO Joseph Papa expects to be the "largest product in Perrigo's 120-year history," comes after the private-labeler's November announcement of a settlement to litigation between Dexcel Pharma and AstraZeneca, the manufacturer of Prilosec OTC (1"The Tan Sheet" Nov. 5, 2007, p. 10). The settlement resolves a legal dispute that began when Dexcel filed a new drug application in April 2006 with a Paragraph IV certification asserting AstraZeneca's Prilosec OTC patents were invalid and would not be infringed by its generic version of the drug (2"The Tan Sheet" June 12, 2006, p. 5)...
You may also be interested in...
Perrigo Expects To Launch Private Label Prilosec OTC In Early 2008
With a major legal hurdle out of the way, Perrigo expects to launch its "largest opportunity" - the first store brand OTC proton pump inhibitor - by the end of March 2008, the firm said Nov. 1
Generic Prilosec OTC ANDA Filed By Perrigo Partner Dexcel; AstraZeneca Sues
Perrigo has acquired marketing rights for a potential generic version of Prilosec OTC, but litigation against the firm's partner Dexcel Pharma by AstraZeneca could block generic OTC omeprazole through 2019
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.